Please login to the form below

Not currently logged in

CureVac says its COVID-19 vaccine can be stored at standard refrigerator temperature

Shot can also be kept at room temperature for 24 hours

German biotech company CureVac has announced that its mRNA-based COVID-19 vaccine has up to 24 hours of stability when stored at room temperature.

CureVac also said that data for its potential COVID-19 vaccine, CVnCoV, suggests the shot remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature - +5 °C (+41°F).

Analytical testing of CVnCoV was performed under standard conditions, as defined by the International Council for Harmonisation of Technical requirements, added CureVac.

“We are very encouraged by the emerging stability profile of our COVID-19 vaccine candidate (which shows it is) compatible with standard fridge-temperature storage as well as a required room temperature application,” said Florian von der Mülbe, chief production officer of CureVac.

“This compatibility has the potential both to enable decentralised storage and to significantly facilitate large-scale vaccination efforts during the current pandemic,” she added.

The stability of CVnCoV was tested at the anticipated storage concentration and also stored at +5°C (+41°F) as well as below -60°C (-76°F), with the vaccine fulfilling all set release specifications at both temperatures after three months.

CureVac added that the stability study of the vaccine remains ongoing, with the aim of further evaluating the potential for a longer commercial product shelf-life.

The Tübingen, Germany-headquarter company seems to have overcome a major distribution obstacle that competitors Pfizer and BioNTech are facing.

On Monday, Pfizer and BioNTech announced the first preliminary data from a phase 3 study of their own mRNA-based vaccine candidate – BNT162b2 – which suggested that the shot is over 90% effective.

However, the companies later added that the vaccine must be stored at an ultra-low temperature – below 70C (94F) – raising certain logistical issues if the vaccine receives regulatory approval soon.

Pfizer said that it is already preparing to distribute its COVID-19 vaccine if it wins regulatory approval, with doses already set to go in its warehouses in the US and Europe, according to the Wall Street Journal (WSJ).

The WSJ also revealed that Pfizer has designed a ‘new reusable container’ that ensures the vaccine can be kept at the ultra-low temperatures required for up to ten days while it is being transported. These containers can hold between 1,000 and 5,000 doses, according to WSJ.

Article by
Lucy Parsons

13th November 2020

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....